Trial Profile
Fluvastatin as out-of-label enhancer for early (EVR) and sustained (SVR) virological response in chronic hepatitis C treated with peginterferon and ribavirin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2011
Price :
$35
*
At a glance
- Drugs Fluvastatin (Primary) ; Peginterferon; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
- 02 May 2010 Results have been presented at Digestive Disease Week (DDW) 2010.
- 26 Apr 2010 New trial record